Insights Into Advanced Ovarian Cancer

Perspectives on current treatment practices in the management of ovarian cancer with regard to molecular testing and first-line and maintenance therapy options

Northeast – December 7, 2020
Purchase Report

Faculty Chair

Michael Birrer, MD, PhD

Winthrop P. Rockefeller Cancer Institute, Little Rock, AR

Example Report

Start discovering the insights

View Report

REPORT SNAPSHOT

  • A moderated roundtable discussion focusing on molecular testing and first-line maintenance treatment of advanced ovarian cancer was held via a virtual platform on December 7, 2020
  • Disease state and data presentations were developed in conjunction with Michael Birrer, MD, PhD, from the Winthrop P. Rockefeller Cancer Institute
  • The group of advisors comprised 12 community oncologists who treat patients with ovarian cancer
  • Insights on the following therapies were obtained: bevacizumab, olaparib, niraparib, rucaparib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • Data collection was accomplished through use of audience response system questioning and moderated discussion
  • Attendees of the roundtable represented community oncologists from Pennsylvania, Vermont, Maryland, New York, and New Jersey

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.